4DMT Announces New Employment Inducement Grants

4D Molecular Therapeutics (Nasdaq: FDMT) reported that on June 9, 2026, its board compensation committee granted 66,900 Restricted Stock Units (RSUs) to seven new non-executive employees.

Rhea-AI Summary

4D Molecular Therapeutics (Nasdaq: FDMT) reported that on June 9, 2026, its board compensation committee granted 66,900 Restricted Stock Units (RSUs) to seven new non-executive employees.

The RSUs were issued under the company’s 2025 Employment Inducement Award Plan pursuant to Nasdaq Rule 5635(c)(4).

Positive

• 66,900 RSUs used to attract seven new non-executive employees
• Equity awards granted under 2025 Employment Inducement Award Plan pursuant to Nasdaq Rule 5635(c)(4)

Negative

• New RSU grants introduce incremental equity dilution for existing shareholders

Argus Jun 15 session

+4.42% close to close Open Argus

Details

News Market Reaction – FDMT

On Jun 15, the first trading day after this news, FDMT closed 4.42% above the previous close.

Data tracked by StockTitan Argus for the Jun 15 session.

Key Figures

RSU grants: 66,900 RSUs Employees granted: 7 employees Plan year: 2025 +1 more

RSU grants

66,900 RSUs

Granted June 9, 2026 to seven new non-executive employees

Employees granted

7 employees

Recipients of inducement RSU awards on June 9, 2026

Plan year

2025

2025 Employment Inducement Award Plan used for these grants

Nasdaq rule

Rule 5635(c)(4)

Nasdaq Global Market rule for employment inducement equity awards

Historical Context

5 past events · Latest: May 27

5 events

1. May 27

   Investor conferences

   24h Move

   +1.6%

   Announced June investor conference presentations and investor meetings.

2. May 15

   Inducement grants

   24h Move

   -8.6%

   Reported 141,100 RSUs granted to 14 new non-executive employees.

3. May 07

   Earnings update

   24h Move

   +2.1%

   Reported Q1 2026 results and clinical milestones with cash runway guidance.

4. May 04

   Investor conferences

   24h Move

   +3.9%

   Outlined May 2026 healthcare conference presentations and webcasts.

5. Apr 17

   Inducement grants

   24h Move

   -4.0%

   Announced 67,600 RSUs to five new non-executive employees.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

restricted stock units, rsus, employment inducement award plan, nasdaq global market

4 terms

restricted stock units financial

"granted seven new non-executive employees 66,900 Restricted Stock Units (RSUs)."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

rsus financial

"granted seven new non-executive employees 66,900 Restricted Stock Units (RSUs)."

RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.

employment inducement award plan financial

"pursuant to the Company’s 2025 Employment Inducement Award Plan, as amended, under Rule 5635(c)(4)"

An employment inducement award plan is a company program that grants stock, stock options, or other equity-based incentives to recruit or retain a specific new employee, similar to offering a signing bonus but paid in company shares. Investors watch these plans because they can dilute existing ownership, change management incentives, and increase compensation expense, all of which can affect share value and future company performance.

nasdaq global market regulatory

"under Rule 5635(c)(4) of The Nasdaq Global Market for equity grants"

The Nasdaq Global Market is a section of the stock exchange where larger, well-established companies are listed and publicly traded. It functions like a marketplace where investors can buy and sell shares of these companies, providing them with access to capital and opportunities for growth. Its role is important because it helps investors identify and invest in reputable companies with strong financial backgrounds.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

EMERYVILLE, Calif., June 12, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that on June 9, 2026, the compensation committee of the Company’s board of directors granted seven new non-executive employees 66,900 Restricted Stock Units (RSUs). The RSUs were granted pursuant to the Company’s 2025 Employment Inducement Award Plan, as amended, under Rule 5635(c)(4) of The Nasdaq Global Market for equity grants to induce new employees to enter into employment with the Company.

About 4DMT

4DMT is a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. The Company’s lead product candidate 4D-150 is designed to be a backbone therapy forming the foundation of treatment of blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) with a single, safe, intravitreal injection, which substantially reduces the treatment burden associated with current bolus injections. The Company’s lead indication for 4D-150 is wet age-related macular degeneration, which is currently in Phase 3 development, and second indication is diabetic macular edema. The Company’s second product candidate is 4D-710, which is the first known genetic medicine to demonstrate successful delivery and expression of the CFTR transgene in the lungs of people with cystic fibrosis after aerosol delivery. 4D Molecular Therapeutics™, 4DMT™, Therapeutic Vector Evolution™, and the 4DMT logo are trademarks of 4DMT.

All of the Company’s product candidates are in clinical or preclinical development and have not yet been approved for marketing by the U.S. Food and Drug Administration or any other regulatory authority. No representation is made as to the safety or effectiveness of the Company’s product candidates for the therapeutic uses for which they are being studied.

Learn more at www.4DMT.com and follow us on LinkedIn.

Contacts:

Media:

Jenn Gordon
dna Communications
Media@4DMT.com

Investors:

Julian Pei
Head of Investor Relations and Strategic Finance
Investor.Relations@4DMT.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What employment inducement grants did 4D Molecular Therapeutics (FDMT) announce on June 12, 2026?

4D Molecular Therapeutics announced inducement grants of 66,900 RSUs to seven new non-executive employees. According to 4D Molecular Therapeutics, these awards were approved on June 9, 2026 by the board’s compensation committee under its 2025 Employment Inducement Award Plan.

How many RSUs did 4D Molecular Therapeutics (FDMT) grant to new employees in June 2026?

4D Molecular Therapeutics granted 66,900 Restricted Stock Units (RSUs) to seven new non-executive hires. According to 4D Molecular Therapeutics, the grants were approved on June 9, 2026 as employment inducement awards under the company’s 2025 Employment Inducement Award Plan.

Under which plan were the new FDMT inducement RSU grants made in June 2026?

The new RSU grants were made under the 2025 Employment Inducement Award Plan. According to 4D Molecular Therapeutics, this plan, as amended, supports equity awards designed to induce new employees to join the company, consistent with Nasdaq Rule 5635(c)(4).

Why did 4D Molecular Therapeutics (FDMT) use Nasdaq Rule 5635(c)(4) for the June 2026 RSU grants?

4D Molecular Therapeutics used Nasdaq Rule 5635(c)(4) to classify the RSUs as inducement awards for new hires. According to 4D Molecular Therapeutics, this rule permits equity grants specifically intended to encourage individuals to enter employment with the company.

How might the June 2026 FDMT inducement RSU grants affect existing shareholders?

The June 2026 inducement grants add 66,900 RSUs, which may create modest future dilution for existing shareholders. According to 4D Molecular Therapeutics, the awards target seven new non-executive employees as part of recruitment and retention efforts.